Abstract
The idea of a preventive vaccine against cancer has been extremely attractive because of the immune system's ability to develop specific and long-lasting immunological memory. Dendritic cells, which present antigen to T cells, sit at a critical point in the activation of the immune system because they are able to activate both B cells and T cells. The first DC vaccines were tested in humans in 1998. In 2010 the first DC vaccine was FDA approved for treatment of patients with advanced prostate cancer. This vaccine showed a survival advantage of 4.3 months. This vaccine was extremely safe, with low rates of adverse events. In this chapter we discuss the history of DC vaccines, the development of DC vaccines including Sipuleucel-T, and the future directions of DC vaccines. This includes strategies for combining DC vaccines with other therapies, including hormone therapy, additional immunotherapy, and chemotherapy.
Original language | English (US) |
---|---|
Title of host publication | Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition |
Publisher | Elsevier Inc. |
Pages | 273-286 |
Number of pages | 14 |
ISBN (Print) | 9780123942968 |
DOIs | |
State | Published - Jul 2013 |
Keywords
- Cancer
- Dendritic cells
- Hormone therapy
- Immunotherapy
- Lymphocyte
- Sipuleucel-T
- Vaccine
ASJC Scopus subject areas
- General Medicine
- General Dentistry